1Roivainen M, Kajander MV, Palosuo T, et al. Infections, inflammation, and the risk of coronary heart disease[J]. Circulation, 2000,101:252-257.
2Austin MA. Epidemiology of hypertriglyceridemia and cardiovascular disease[J]. Am J Cardiol, 1999,83:13F-16F.
3Aikama M, Rabkin E, Okada Y, et al. Lipid Lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma[J]. Circulation, 1998,97:2433-2444.
4Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction[J]. Circulation, 1998,97:2007-2011.
5Jianhui Zhu, Quyyumi AA, Norman JE, et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels[J]. Am J Cardiol, 2000,85:140-146.
6Wolf MG, Zasmeta G, Hornykewycz S, et al. Plasma levels of C-reactive protein after coronary stent implantation[J]. Eur Heart J, 2000,21:1152-1158.
7The ENCORE trials. Endothelial dysfunction as a therapeutic target[J]. Eur Heart J Supplements, 2000,1(Suppl D):D20-D25.
8Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease[J]. Lancet,1999,353:118-119.
9Ridker PM, Rifai N, Pfeffer MA, et al. Long term effects of pravastatin on plasma concentration of C-reactive protein[J]. Circulation, 1999,100:230-235.
